Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Enzon Pharmaceuticals Inc
ENZN | US
5.95
USD-0.05
-0.83%
ENZN | US
Loading StockChartView...
About Enzon Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
5.95
Open
5.95
High
5.95
Low
5.95
Enzon Pharmaceuticals Inc. together with its subsidiaries engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford New Jersey.
View LessENZN | US
Risk
83.2
Sharpe
-0.27
Luna's Score
46/100
Recommendation
Hold
Luna says (ENZN | US)
What's Working
Positive Momentum
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
48.1%1 month
83.2%3 months
103.5%6 months
131.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
12.00
Fwd. PE
-
Price to book
2.86
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
38.29
Ent. to rev.
608.03
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
424.25M
MarketCap(USD)
424.25M
Div. yield
-
Op. margin
-1.25K
Erngs. growth
29.10
Rev. growth
-10.30
Ret. on equity
3.42
Short ratio
1.71
Short perc.
0.68
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.40
Range1M
0.94
Range3M
6.99
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.31
Price X volume
2.97K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 38.29 | 0.53 | Expensive |
| Ent. to Revenue | 608.03 | 3,967.00 | Cheaper |
| PE Ratio | 12.00 | 41.03 | Cheaper |
| Price to Book | 2.86 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 103.47 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 424.25M | 3.66B | Emerging |
